10 November 2020 — Global Research

By Dr. Binoy Kampmark

The announcement that Pfizer Inc., along with its collaborative partner BioNTech SE, had come up with a successful vaccine candidate to combat the novel coronavirus SARS-CoV-2 sent the markets soaring.  In New York, Pfizer’s shares rose by 15 percent in pre-market trading; those of BioNTech, Nasdaq-listed, rose 25 percent.  “Today is a great day for science and humanity,” a confident Pfizer Chairman and CEO Albert Bourla crowed.  “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”